Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

NCT00297687 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

NCT03135834 ·Status: COMPLETED ·Phase: PHASE3

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Healthy Toddlers

NCT00387569 ·Status: COMPLETED ·Phase: PHASE1

Chikungunya Virus Vaccine Trial in Healthy Adults

NCT01489358 ·Status: COMPLETED ·Phase: PHASE1

Research Study to Assess New Chikungunya and Zika Vaccines in Healthy Adults in Mexico.

NCT04440774 ·Status: COMPLETED ·Phase: PHASE1

A Phase 1/2/3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children

NCT04816643 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years

NCT03587207 ·Status: COMPLETED ·Phase: PHASE2

A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years

NCT01299480 ·Status: COMPLETED ·Phase: PHASE2

A Study Evaluating Safety And Immunogenicity Of Meningococcal B Rlp2086 Vaccine In Adolescents

NCT00808028 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years.

NCT01352845 ·Status: COMPLETED ·Phase: PHASE3

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

NCT02531698 ·Status: COMPLETED ·Phase: PHASE2

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

NCT03483961 ·Status: COMPLETED ·Phase: PHASE2

Study Evaluating Safety, Tolerability, and Immunogenicity of Meningococcal B Vaccine in Healthy Infants

NCT00798304 ·Status: TERMINATED ·Phase: PHASE2

A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age

NCT04796896 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Phase I Trial of Measles Vectored Chikungungya Vaccine

NCT03028441 ·Status: COMPLETED ·Phase: PHASE1

Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli)

NCT06314880 ·Status: RECRUITING ·Phase: PHASE1

Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine (V184-005)

NCT03635086 ·Status: COMPLETED ·Phase: PHASE2

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

NCT02861586 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

NCT01830855 ·Status: COMPLETED ·Phase: PHASE3

Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and Infants

NCT03507738 ·Status: COMPLETED ·Phase: PHASE1

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

NCT01323270 ·Status: COMPLETED ·Phase: PHASE2

A Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults

NCT06680128 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)

NCT00836498 ·Status: TERMINATED ·Phase: PHASE1

Study of Meningococcal B Vaccine and ACWY Conjugate Vaccine in Healthy Adults

NCT00962624 ·Status: COMPLETED ·Phase: PHASE2

Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine Given as One Dose to Healthy Subjects Above 56 Years

NCT01235975 ·Status: COMPLETED ·Phase: PHASE3